This 2014 review article provides a comprehensive overview of emerging pharmacological treatments for obesity, focusing on novel agents and therapeutic targets under investigation at the time. The authors discuss several new drug classes, including GLP-1 receptor agonists (e.g., semaglutide), melanocortin-4 receptor agonists (e.g., setmelanotide), and dual amylin and calcitonin receptor
